ORIC® Pharmaceuticals To Participate In Upcoming Investor Conferences
- Wells Fargo 21 st Annual Healthcare Conference – Participating in a fireside chat on Wednesday, September 9, 2026, at 2:15 p.m. ET. Management will also be participating in one-on-one meetings.
2026 Cantor Global Healthcare Conference – Participating in a fireside chat on Thursday, September 10, 2026, at 1:35 p.m. ET. Management will also be participating in one-on-one meetings.
Morgan Stanley 24 th Annual Global Healthcare Conference – Participating in a fireside chat on Tuesday, September 15, 2026, at 10:00 a.m. ET. Management will also be participating in one-on-one meetings.
Webcasts of the fireside chat discussions will be available through the investor section of the company's website at . Replays of the webcasts will be available for 90 days following the event.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer. ORIC's clinical stage product candidates include (1) rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain-penetrant inhibitor targeting EGFR exon 20 insertion and EGFR atypical mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to , and follow us on X or LinkedIn.
Contact:
Dominic Piscitelli, Chief Financial Officer
...
...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment